Yiğit, EceÜnsal, Saadet2025-06-102025-06-102024Yiğit, E. ve Ünsal, S. (2024). Isoflavones obtained from red clover improve both dyslipidemia and menopausal symptoms in menopausal women: a prospective randomized placebo-controlled trial. Climacteric, 27(6), 548-554. http://dx.doi.org/10.1080/13697137.2024.23931211369-7137http://dx.doi.org/10.1080/13697137.2024.23931211473-0804https://hdl.handle.net/20.500.12511/12938Objective: This study aimed to investigate the effects of red clover isoflavones on menopausal symptoms and the lipid profile in menopausal females. Methods: This study included postmenopausal women with dyslipidemia. The red clover group (n = 39) received 40 mg isoflavone red clover capsule twice daily for 6 months, while placebo (n = 36) was 40 mg starch capsule twice daily. Data were collected at baseline, 3 months and 6 months. The Menopause Rating Scale (MRS) was applied to calculate subdimension and total scores. Results: The two groups were similar in terms of age, MRS and lipid profile at baseline. In the red clover group, MRS scores decreased significantly at both 3 and 6 months. Similarly, total cholesterol, low-density lipoprotein cholesterol (LDL-C) and triglyceride levels decreased at both 3 months and 6 months. High-density lipoprotein cholesterol increased significantly from baseline to 3 months and 6 months. Except for LDL-C and MRS urogenital score at 3 months, the improvements were significantly in favor of red clover isoflavone treatment. Conclusions: Red clover treatment for 3–6 months demonstrated significant improvements in lipid profiles and menopausal symptoms. While promising, further research is crucial to ascertain long-term safety and recommend the use of red clover isoflavones during menopause.eninfo:eu-repo/semantics/openAccessDyslipidemiaMenopauseMenopause Rating ScalePlaceboRed CloverArticle27654855410.1080/13697137.2024.2393121Q1WOS:0013090579000012-s2.0-8520342619139254422Q1